New research highlights genetic modifications that enhance CAR T cell persistence and efficacy in multiple myeloma models. Using CRISPR screening, scientists identified gene knockouts such as CDKN1B deletion that improve T cell proliferation and anti-tumor activity in vivo. Additionally, advanced glycan-dependent T cell recruiters (GlyTRs) show promising pan-cancer capacity, and an innovative injectable stem cell therapy offers potential for restoring muscle function. These developments represent major strides in overcoming immunotherapy resistance and expanding therapeutic options.